1. Home
  2. CYCC vs BACK Comparison

CYCC vs BACK Comparison

Compare CYCC & BACK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • BACK
  • Stock Information
  • Founded
  • CYCC 1992
  • BACK 2000
  • Country
  • CYCC United States
  • BACK United States
  • Employees
  • CYCC N/A
  • BACK N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • BACK Medical Specialities
  • Sector
  • CYCC Health Care
  • BACK Health Care
  • Exchange
  • CYCC Nasdaq
  • BACK Nasdaq
  • Market Cap
  • CYCC 1.8M
  • BACK 2.1M
  • IPO Year
  • CYCC N/A
  • BACK 2019
  • Fundamental
  • Price
  • CYCC $0.37
  • BACK $1.03
  • Analyst Decision
  • CYCC Buy
  • BACK
  • Analyst Count
  • CYCC 2
  • BACK 0
  • Target Price
  • CYCC $11.00
  • BACK N/A
  • AVG Volume (30 Days)
  • CYCC 3.7M
  • BACK 36.3K
  • Earning Date
  • CYCC 11-12-2024
  • BACK 11-26-2024
  • Dividend Yield
  • CYCC N/A
  • BACK N/A
  • EPS Growth
  • CYCC N/A
  • BACK N/A
  • EPS
  • CYCC N/A
  • BACK N/A
  • Revenue
  • CYCC $74,000.00
  • BACK N/A
  • Revenue This Year
  • CYCC N/A
  • BACK N/A
  • Revenue Next Year
  • CYCC $16.28
  • BACK N/A
  • P/E Ratio
  • CYCC N/A
  • BACK N/A
  • Revenue Growth
  • CYCC N/A
  • BACK N/A
  • 52 Week Low
  • CYCC $0.35
  • BACK $1.00
  • 52 Week High
  • CYCC $6.00
  • BACK $7.75
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 29.98
  • BACK 35.53
  • Support Level
  • CYCC $0.35
  • BACK $1.00
  • Resistance Level
  • CYCC $0.52
  • BACK $1.35
  • Average True Range (ATR)
  • CYCC 0.07
  • BACK 0.10
  • MACD
  • CYCC -0.01
  • BACK -0.02
  • Stochastic Oscillator
  • CYCC 3.94
  • BACK 5.68

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

About BACK IMAC Holdings Inc.

IMAC Holdings Inc is a provider and manager of value-based, conservative medical care combining life science advancements with traditional medical care for movement-restricting diseases and conditions in IMAC Regeneration Centers and BackSpace clinics. Its Innovative Medical Advancements and Care (IMAC) Regeneration Centers combine medical and physical procedures to improve patient experiences and outcomes and reduce healthcare costs as compared to other available treatment options.

Share on Social Networks: